替莫唑胺对<i>Livin</i>基因过表达的胶质瘤TJ905细胞及其干细胞增殖活性的影响

doi:10.3877/cma.j.issn.2095-123X.2020.02.008

中华脑科疾病与康复杂志(电子版) ›› 2020, Vol. 10 ›› Issue (02) : 99 -105. doi: 10.3877/cma.j.issn.2095-123X.2020.02.008

所属专题：文献；

基础研究

替莫唑胺对Livin基因过表达的胶质瘤TJ905细胞及其干细胞增殖活性的影响

李根华¹, 冯嵩¹, 韩光魁¹, 马文渊², 刘臣², 孔令胜¹, 靳峰¹^,^†(

)

^1. 272029　济宁，济宁医学院附属医院神经外科暨山东省干细胞与神经肿瘤学重点实验室
^2. 272067　济宁，济宁医学院临床医学院

收稿日期:2020-04-05 出版日期:2020-04-15
通信作者: 靳峰
基金资助:
山东省医药卫生科技发展计划项目(2016WS0180); 山东省自然科学基金资助项目(ZR2016HL34); 山东省高等学校科技计划项目(J16LL05); 济宁医学院教师科研扶持基金(JYFC2018FKJ139)

Effect of temozolomide on cell proliferation in TJ905 glioma stem cells with Livin over-expression

Genhua Li¹, Song Feng¹, Guangkui Han¹, Wenyuan Ma², Chen Liu², Lingsheng Kong¹, Feng Jin¹^,^†()

^1. Department of Neurosurgery, Affiliated Hospital of Jining Medical University & Shandong Provincial Key Laboratory of Stem Cells and Neuro-oncology, Jining 272029, China
^2. Clinical Medical College, Jining Medical University, Jining 272067, China

Received:2020-04-05 Published:2020-04-15
Corresponding author: Feng Jin

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

李根华, 冯嵩, 韩光魁, 马文渊, 刘臣, 孔令胜, 靳峰. 替莫唑胺对Livin基因过表达的胶质瘤TJ905细胞及其干细胞增殖活性的影响[J]. 中华脑科疾病与康复杂志(电子版), 2020, 10(02): 99-105.

Genhua Li, Song Feng, Guangkui Han, Wenyuan Ma, Chen Liu, Lingsheng Kong, Feng Jin. Effect of temozolomide on cell proliferation in TJ905 glioma stem cells with Livin over-expression[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2020, 10(02): 99-105.

目的

分析替莫唑胺（TMZ）干预Livin基因过表达的胶质瘤TJ905细胞及其干细胞模型后对细胞增殖活性的影响，以及对胶质瘤TJ905细胞和TJ905干细胞中Livin、Caspase-3/7的作用机制。

方法

使用免疫磁珠方法从胶质瘤TJ905细胞系中分选出CD133阳性胶质瘤干细胞，采用慢病毒过表达技术建立Livin过表达的细胞模型，使用不同浓度（0、25、50、100、200、400 μmol/L）的TMZ干预细胞模型48 h，采用CCK-8、流式细胞术、反转录PCR检测药物干预后细胞增殖活性、细胞周期及Livin、Caspase-3/7基因的表达量。

结果

（1）胶质瘤TJ905细胞中Livin基因表达量明显高于同源TJ905干细胞，差异有统计学意义（P<0.05）；（2）TMZ能抑制胶质瘤TJ905细胞及其干细胞的增殖活性，降低增殖速度，并且随药物浓度的增加抑制作用逐渐增强；（3）TMZ能抑制Livin基因的表达，诱导Caspase-3/7的表达，并且随药物浓度的增加抑制作用逐渐增强，差异有统计学意义（P<0.05）；（4）Livin基因转染后胶质瘤干细胞细胞周期G0/G1增加明显，而TJ905细胞周期则是G2/M期少量增加；TMZ干预细胞模型后，TJ905干细胞过表达组在S、G2/M停滞，对照组则是在S期停滞；TJ905细胞过表达组在S期停滞，对照组G2/M则是低浓度诱导停滞，随药物浓度增加其诱导作用减弱，差异均有统计学意义（P<0.05）。

结论

TMZ可以通过抑制Livin基因的表达、诱导Caspase-3/7的表达、调控细胞周期变化来降低细胞增殖活性，促进细胞凋亡。

关键词: Livin, Caspase-3/7, TJ905干细胞, 替莫唑胺, 细胞增殖

Objective

To analyze the effect of cell proliferation after temozolomide (TMZ) intervention in TJ905 cells and stem cells with Livin gene overexpression. To explore the mechanism for TMZ to Livin and Caspase-3/7 in glioma TJ905 cells and stem cells.

Methods

CD133 positive TJ905 glioma cells were separated by immunomagnetic beads to isolate glioma stem cells, to establish the overexpression cell models of Livin gene with lentivirus transfection technology. Livin over-expression cell models were intervened by different concentration of TMZ for 48 h. Cell counting kit-8 assay, flow cytometry, reverse transcription-PCR were used to analyze cell cycle to investigate cell proliferation and to detect the expression of Livin and Caspase-3/7 respectively, following treatment with various concentrations of TMZ (0, 25, 50, 100, 200 and 400 μmol/L) for 48 h.

Results

(1)The expression of Livin gene in glioma TJ905 cells was significantly higher than that of TJ905 stem cells (P<0.05); (2)TMZ could inhibit the proliferation of glioma TJ905 cells and stem cells, and the inhibitory effect increased with the increase of drug concentration; (3)TMZ could inhibit the expression of Livin gene and induce the expression of Caspase- 3/7. With the increase of drug concentration, the inhibitory effect gradually increased, and the difference was statistically significant (P<0.05); (4)After Livin gene transfection, the cell cycle G0/G1 of TJ905 stem cellsincreased significantly, while TJ905 cell cycle increased slightly in G2/M phase. after TMZ intervention, TJ905 stem cell overexpression group stopped in S and G2/M phase, while that in control group was in S phase. TJ905 cellsoverexpression group stopped in S phase in the overexpression group, while G2/M in the control group was induced by low concentration, the induction effect was weakened with the increase of drug concentration, and the differences were statistically significant (P<0.05).

Conclusion

TMZ can inhibit the expression of Livin gene, induce the expression of Caspase-3/7, and regulate the changes of cell cycle to reduce the proliferation activity and promote apoptosis.

Key words: Livin, Caspase-3/7, TJ905 stem cells, Temozolomide, Cell proliferation

表1 引物序列

基因	引物序列
Homo-Livin	Forward：5 ’-GCTGTCAGTTCCTGCTCCGGTC-3 ’
	Reverse：5 ’-CAGGGGCTGCGTCTTCCGGTTC-3 ’
Homo-Caspase-3	Forward：5 ’-GAAGCGAATCAATGGACTCTGG-3 ’
	Reverse：5 ’-GTTTGCTGCATCGACATCTGTAC-3 ’
Homo-Caspase-7	Forward：5 ’-CCTCGTTTGTACCGTCCCTCTT-3 ’
	Reverse：5 ’-GGCATCTTTGTCTGTTCCGTTTC-3 ’
Homo-GAPDH	Forward：5 ’-GGAGCGAGATCCCTCCAAAAT-3 ’
	Reverse：5 ’-GGCTGTTGTCATACTTCTCATGG-3 ’

表1 引物序列

基因	引物序列
Homo-Livin	Forward：5 ’-GCTGTCAGTTCCTGCTCCGGTC-3 ’
	Reverse：5 ’-CAGGGGCTGCGTCTTCCGGTTC-3 ’
Homo-Caspase-3	Forward：5 ’-GAAGCGAATCAATGGACTCTGG-3 ’
	Reverse：5 ’-GTTTGCTGCATCGACATCTGTAC-3 ’
Homo-Caspase-7	Forward：5 ’-CCTCGTTTGTACCGTCCCTCTT-3 ’
	Reverse：5 ’-GGCATCTTTGTCTGTTCCGTTTC-3 ’
Homo-GAPDH	Forward：5 ’-GGAGCGAGATCCCTCCAAAAT-3 ’
	Reverse：5 ’-GGCTGTTGTCATACTTCTCATGG-3 ’

图1 慢病毒转染前后胶质瘤TJ905细胞及其干细胞显微镜下观察

表2 CCK-8检测TMZ干预各组细胞48 h后细胞增殖活性

TMZ浓度	ACC		CSC
TMZ浓度	CON	OE	CON	OE
0 μmol/L（Control）	1.202±0.045	1.347±0.068	0.650±0.020	0.753±0.018
25 μmol/L	1.157±0.065	1.263±0.066	0.635±0.019	0.673±0.021^a
50 μmol/L	1.033±0.063^a	1.150±0.079^a	0.528±0.016^a	0.555±0.012^a
100 μmol/L	0.901±0.032^a	1.121±0.098^a	0.453±0.011^a	0.474±0.021^a
200 μmol/L	0.863±0.022^a	1.094±0.082^a	0.437±0.021^a	0.445±0.014^a
400 μmol/L	0.816±0.021^a	0.982±0.098^a	0.383±0.019^a	0.403±0.017^a
F值	32.642	6.895	111.962	188.866
P值	<0.001	0.003	<0.001	<0.001

表2 CCK-8检测TMZ干预各组细胞48 h后细胞增殖活性

TMZ浓度	ACC		CSC
TMZ浓度	CON	OE	CON	OE
0 μmol/L（Control）	1.202±0.045	1.347±0.068	0.650±0.020	0.753±0.018
25 μmol/L	1.157±0.065	1.263±0.066	0.635±0.019	0.673±0.021^a
50 μmol/L	1.033±0.063^a	1.150±0.079^a	0.528±0.016^a	0.555±0.012^a
100 μmol/L	0.901±0.032^a	1.121±0.098^a	0.453±0.011^a	0.474±0.021^a
200 μmol/L	0.863±0.022^a	1.094±0.082^a	0.437±0.021^a	0.445±0.014^a
400 μmol/L	0.816±0.021^a	0.982±0.098^a	0.383±0.019^a	0.403±0.017^a
F值	32.642	6.895	111.962	188.866
P值	<0.001	0.003	<0.001	<0.001

表3 RT-PCR检测TMZ干预各组细胞48 h Livin mRNA表达变化（×10^-5）

TMZ浓度	ACC-OE	CSC-OE	t值	P值	ACC-CON	CSC-CON	t值	P值
0 μmol/L（Control）	564.113±21.951	84.315±1.808	-37.732	<0.001	245.777±14.176^b	27.025±3.895^b	-25.773	<0.001
25 μmol/L	391.114±6.444^a	59.191±2.032^a	-85.083	<0.001	124.651±8.176^a	12.366±1.684^a	-23.297	<0.001
50 μmol/L	370.328±11.541^a	58.190±1.582^a	-46.410	<0.001	100.874±10.516^a	8.502±1.286^a	-15.101	<0.001
100 μmol/L	315.832±10.691^a	46.150±2.042^a	-42.917	<0.001	82.033±7.470^a	7.842±0.524^a	-17.159	<0.001
200 μmol/L	223.033±9.489^a	38.270±1.779^a	-33.131	<0.001	59.741±6.982^a	7.710±0.454^a	-12.881	<0.001
400 μmol/L	169.745±8.608^a	29.555±2.523^a	-27.068	<0.001	28.807±3.895^a	6.694±0.697^a	-9.691	0.001
F值	373.502	283.050			206.544	52.685
P值	<0.001	<0.001			<0.001	<0.001

表3 RT-PCR检测TMZ干预各组细胞48 h Livin mRNA表达变化（×10^-5）

TMZ浓度	ACC-OE	CSC-OE	t值	P值	ACC-CON	CSC-CON	t值	P值
0 μmol/L（Control）	564.113±21.951	84.315±1.808	-37.732	<0.001	245.777±14.176^b	27.025±3.895^b	-25.773	<0.001
25 μmol/L	391.114±6.444^a	59.191±2.032^a	-85.083	<0.001	124.651±8.176^a	12.366±1.684^a	-23.297	<0.001
50 μmol/L	370.328±11.541^a	58.190±1.582^a	-46.410	<0.001	100.874±10.516^a	8.502±1.286^a	-15.101	<0.001
100 μmol/L	315.832±10.691^a	46.150±2.042^a	-42.917	<0.001	82.033±7.470^a	7.842±0.524^a	-17.159	<0.001
200 μmol/L	223.033±9.489^a	38.270±1.779^a	-33.131	<0.001	59.741±6.982^a	7.710±0.454^a	-12.881	<0.001
400 μmol/L	169.745±8.608^a	29.555±2.523^a	-27.068	<0.001	28.807±3.895^a	6.694±0.697^a	-9.691	0.001
F值	373.502	283.050			206.544	52.685
P值	<0.001	<0.001			<0.001	<0.001

表4 RT-PCR检测TMZ干预各组细胞48 h Caspase-3 mRNA表达变化（×10^-5）

TMZ浓度	ACC-OE	CSC-OE	t值	P值	ACC-CON	CSC-CON	t值	P值
0 μmol/L（Control）	0.402±0.037	0.373±0.049	0.709	0.461	6.205±0.650^b	85.348±3.371^b	39.927	<0.001
25 μmol/L	0.496±0.116	1.668±0.206^a	8.582	0.001	10.652±1.929^a	217.061±13.311^a	26.579	<0.001
50 μmol/L	0.631±0.094^a	1.770±0.188^a	9.367	0.001	13.253±2.038^a	338.321±12.657^a	43.919	<0.001
100 μmol/L	0.730±0.088^a	3.341±0.315^a	13.822	<0.001	19.978±3.564^a	565.944±13.130^a	69.508	<0.001
200 μmol/L	1.063±0.160^a	4.255±0.381^a	13.370	<0.001	22.781±2.882^a	653.046±9.249^a	112.691	<0.001
400 μmol/L	1.238±0.213^a	5.617±0.346^a	18.691	<0.001	37.649±3.999^a	731.297±19.467^a	60.454	<0.001
F值	18.872	150.354			49.859	1210.881
P值	<0.001	<0.001			<0.001	<0.001

表4 RT-PCR检测TMZ干预各组细胞48 h Caspase-3 mRNA表达变化（×10^-5）

TMZ浓度	ACC-OE	CSC-OE	t值	P值	ACC-CON	CSC-CON	t值	P值
0 μmol/L（Control）	0.402±0.037	0.373±0.049	0.709	0.461	6.205±0.650^b	85.348±3.371^b	39.927	<0.001
25 μmol/L	0.496±0.116	1.668±0.206^a	8.582	0.001	10.652±1.929^a	217.061±13.311^a	26.579	<0.001
50 μmol/L	0.631±0.094^a	1.770±0.188^a	9.367	0.001	13.253±2.038^a	338.321±12.657^a	43.919	<0.001
100 μmol/L	0.730±0.088^a	3.341±0.315^a	13.822	<0.001	19.978±3.564^a	565.944±13.130^a	69.508	<0.001
200 μmol/L	1.063±0.160^a	4.255±0.381^a	13.370	<0.001	22.781±2.882^a	653.046±9.249^a	112.691	<0.001
400 μmol/L	1.238±0.213^a	5.617±0.346^a	18.691	<0.001	37.649±3.999^a	731.297±19.467^a	60.454	<0.001
F值	18.872	150.354			49.859	1210.881
P值	<0.001	<0.001			<0.001	<0.001

表5 RT-PCR检测TMZ干预各组细胞48 h Caspase-7 mRNA表达变化（×10^-5）

TMZ浓度	ACC-OE	CSC-OE	t值	P值	ACC-CON	CSC-CON	t值	P值
0 μmol/L（Control）	95.839±5.052	806.186±24.394	49.388	<0.001	61.244±5.509^b	270.929±11.133^b	29.238	<0.001
25 μmol/L	124.723±7.997^a	816.711±13.702	75.547	<0.001	87.178±5.667^a	335.756±66.896	6.413	0.003
50 μmol/L	172.900±9.026^a	888.467±14.973^a	70.890	<0.001	106.602±5.509^a	443.033±7.146^a	55.976	<0.001
100 μmol/L	191.808±12.025^a	894.998±16.521^a	59.605	<0.001	132.607±8.516^a	470.861±12.542^a	38.645	<0.001
200 μmol/L	203.437±13.704^a	943.922±16.818^a	59.120	<0.001	144.517±11.525^a	479.872±19.830^a	25.325	<0.001
400 μmol/L	240.911±10.331^a	943.922±16.818^a	33.544	<0.001	145.369±11.801^a	487.589±17.463^a	28.123	<0.001
F值	83.582	40.811			45.043	26.429
P值	<0.001	<0.001			<0.001	<0.001

表5 RT-PCR检测TMZ干预各组细胞48 h Caspase-7 mRNA表达变化（×10^-5）

TMZ浓度	ACC-OE	CSC-OE	t值	P值	ACC-CON	CSC-CON	t值	P值
0 μmol/L（Control）	95.839±5.052	806.186±24.394	49.388	<0.001	61.244±5.509^b	270.929±11.133^b	29.238	<0.001
25 μmol/L	124.723±7.997^a	816.711±13.702	75.547	<0.001	87.178±5.667^a	335.756±66.896	6.413	0.003
50 μmol/L	172.900±9.026^a	888.467±14.973^a	70.890	<0.001	106.602±5.509^a	443.033±7.146^a	55.976	<0.001
100 μmol/L	191.808±12.025^a	894.998±16.521^a	59.605	<0.001	132.607±8.516^a	470.861±12.542^a	38.645	<0.001
200 μmol/L	203.437±13.704^a	943.922±16.818^a	59.120	<0.001	144.517±11.525^a	479.872±19.830^a	25.325	<0.001
400 μmol/L	240.911±10.331^a	943.922±16.818^a	33.544	<0.001	145.369±11.801^a	487.589±17.463^a	28.123	<0.001
F值	83.582	40.811			45.043	26.429
P值	<0.001	<0.001			<0.001	<0.001

图2 TMZ干预各组细胞48 h细胞周期变化

表6 流式细胞仪检测TMZ干预48 h细胞周期变化（%）

TMZ浓度	CSC-OE S期（%）	CSC-OE G2/M期（%）	CSC-CON S期（%）	ACC-OE S期（%）	ACC-CON G2/M期（%）
0 μmol/L（Control）	9.35±0.81	5.65±1.52	29.72±1.89	14.64±2.20	6.84±1.11
25 μmol/L	7.23±0.89^a	6.70±0.51	32.78±2.20	31.59±1.80^a	7.37±1.20
50 μmol/L	9.37±0.64	7.23±1.28	43.54±1.95^a	40.70±2.10^a	8.66±1.37
100 μmol/L	9.02±1.41	7.91±1.43	54.40±2.96^a	47.73±2.08^a	10.78±1.78^a
200 μmol/L	15.47±1.30^a	11.90±1.01^a	63.97±2.35^a	64.47±2.80^a	15.34±1.95^a
400 μmol/L	27.39±1.54^a	17.51±1.27^a	64.50±2.42^a	67.55±1.60^a	39.28±1.94^a
F值	134.639	40.869	128.412	261.740	182.311
P值	<0.001	<0.001	<0.001	<0.001	<0.001

表6 流式细胞仪检测TMZ干预48 h细胞周期变化（%）

TMZ浓度	CSC-OE S期（%）	CSC-OE G2/M期（%）	CSC-CON S期（%）	ACC-OE S期（%）	ACC-CON G2/M期（%）
0 μmol/L（Control）	9.35±0.81	5.65±1.52	29.72±1.89	14.64±2.20	6.84±1.11
25 μmol/L	7.23±0.89^a	6.70±0.51	32.78±2.20	31.59±1.80^a	7.37±1.20
50 μmol/L	9.37±0.64	7.23±1.28	43.54±1.95^a	40.70±2.10^a	8.66±1.37
100 μmol/L	9.02±1.41	7.91±1.43	54.40±2.96^a	47.73±2.08^a	10.78±1.78^a
200 μmol/L	15.47±1.30^a	11.90±1.01^a	63.97±2.35^a	64.47±2.80^a	15.34±1.95^a
400 μmol/L	27.39±1.54^a	17.51±1.27^a	64.50±2.42^a	67.55±1.60^a	39.28±1.94^a
F值	134.639	40.869	128.412	261.740	182.311
P值	<0.001	<0.001	<0.001	<0.001	<0.001

[4]	Ledur PF, Villodre ES, Paulus R, et al. Extracellular ATP reduces tumor sphere growth and cancer stem cell population in glioblastoma cells[J]. Purinergic Signal, 2012, 8(1): 39-48.
[5]	Ashhab Y, Alian A, Polliack A, et al. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern[J]. FEBS Lett, 2001, 495(1-2): 56-60.
[6]	Ghods AJ, Irvin D, Liu G, et al. Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells[J]. Stem Cells, 2007, 25(7): 1645-1653.
[7]	Erguven M, Bilir A, Yazihan N, et al. Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine[J]. Cancer Cell Int, 2011, 11(1): 18.
[8]	Kanzawa T, Germano IM, Komata T, et al. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells[J]. Cell Death Differ, 2004, 11(4): 448-457.
[9]	Hassler M, Micksche M, Stockhammer G, et al. Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study[J]. Wiener Klin Wochenschr, 2006, 118(7-8): 230-238.
[10]	Yan B. Research progress on livin protein: an inhibitor of apoptosis[J]. Mol Cell Biochem, 2011, 357(1-2): 39-45.
[11]	Häcker HG, Sisay MT, Gütschow M. Allosteric modulation of caspases[J]. Pharmacol Ther, 2011, 132(2): 180-195.
[12]	Wright KM, Vaughn AE, Deshmukh M. Apoptosome dependent caspase-3 activation pathway is non-redundant and necessary for apoptosis in sympathetic neurons[J]. Cell Death Differ, 2007, 14(3): 625-633.
[13]	Biegańska K, Sokolowska P, Johren O, et al. Orexin a suppresses the growth of rat C6 glioma cells via a caspase-dependent mechanism[J]. J Mol Neurosci, 2012, 48(3): 706-712.
[14]	Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma[J]. Mol Cancer, 2006, 5: 67.
[15]	Li GH, Zhang H, Liu Y, et al. Effect of temozolomide on livin and caspase-3 in U251 glioma stem cells[J]. Exp and Ther Med, 2015, 9(3): 744-750.
[1]	Erguven M, Bilir A, Yazihan N, et al. Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine[J]. Cancer Cell Int, 2011, 11(1): 18.
[2]	Zhang P, Chen XB, Ding BQ, et al. Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway[J]. Bioscience Reports, 2018, 38(6): BSR20181711.
[3]	Chen L, Zhang J, Han L, et al. Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status[J]. Oncol Rep, 2012, 27(3): 854-860.

[1]	程慧, 李妍雨, 张蓓, 成杰, 张艳玲. 微小RNA-195靶向趋化因子5抑制滋养细胞增殖、迁移和侵袭及其机制研究[J]. 中华妇幼临床医学杂志(电子版), 2022, 18(02): 165-174.
[2]	孙佳辰, 宋垚垚, 申传安, 赵虹晴, 孙天骏. 表皮和表皮干细胞衰老的研究进展[J]. 中华损伤与修复杂志(电子版), 2022, 17(06): 531-534.
[3]	江振剑, 蒋明, 黄大莉. TK1、Ki67蛋白在分化型甲状腺癌组织中的表达及预后价值研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 623-626.
[4]	石浩伟, 郝少龙, 纪宇, 孙浩, 聂芳, 胡阳, 李泽乾, 韩威. 长链非编码RNA-BANCR在胰腺癌中的表达及临床意义[J]. 中华普外科手术学杂志(电子版), 2022, 16(05): 554-559.
[5]	雷震, 郭正辉, 唐晨, 彭圣萌, 任艳婷, 吴宛桦, 周杰, 陈勇明, 李凌峰, 黄海, 赖义明. ASF1B通过调控P53相关信号通路促进前列腺癌迁移和增殖的研究[J]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(03): 262-269.
[6]	李芬, 黄文娟, 朱乐攀. 色素上皮因子表达对肺癌细胞增殖及迁移能力的影响[J]. 中华肺部疾病杂志(电子版), 2022, 15(02): 246-248.
[7]	刘燕, 叶亚萍, 郑艳莉. 干扰LINC00466通过miR-493-3p/MIF抑制子宫内膜癌RL95-2细胞恶性生物学行为[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(03): 151-158.
[8]	梁芳, 刘广申, 徐艳. LncRNA AC130710通过miR-129-5P/WNT4轴促进子宫内膜癌细胞增殖和上皮间质转化[J]. 中华细胞与干细胞杂志(电子版), 2022, 12(04): 206-214.
[9]	董会月, 张晓, 祝玲, 张怡, 孙晶晶, 路君. TET3促进肾透明细胞癌细胞增殖[J]. 中华细胞与干细胞杂志(电子版), 2021, 11(06): 337-342.
[10]	莫钊鸿, 翟航, 苏日顺, 孟泓宇, 罗豪, 陈文豪, 许瑞云. U2AF2表达对肝细胞癌增殖和迁移的影响及其与预后的关系[J]. 中华肝脏外科手术学电子杂志, 2023, 12(03): 336-341.
[11]	魏志鸿, 郭娟, 江哲龙, 江艺, 吕立志. miR-4458靶向结合BZW2对肝癌细胞增殖、迁移和侵袭的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(01): 108-113.
[12]	汤永昌, 袁峰, 梁豪, 钟昭众, 熊志勇, 曹明波, 任昱朋, 李宇轩, 姚志成, 邓美海. HBx对HBV相关性肝癌增殖和迁移能力的影响及其机制[J]. 中华肝脏外科手术学电子杂志, 2022, 11(02): 198-202.
[13]	杨翠萍, 杨晓金, 全旭, 谢玲, 吴云林, 陈平. 肝细胞核因子-1α基因突变协同腺瘤样结肠息肉病基因突变对家族性腺瘤性息肉病细胞增殖的影响[J]. 中华消化病与影像杂志(电子版), 2022, 12(04): 228-231.
[14]	张懿炜, 胡亚欣, 出良钊, 严昭, 曾茜, 蒲茜. CREB3通过下调FAK磷酸化水平抑制胶质瘤细胞增殖及侵袭转移的体外实验研究[J]. 中华临床医师杂志(电子版), 2023, 17(02): 202-209.
[15]	郭德华, 贺迎坤, 白卫星, 何艳艳, 李天晓. 脑动静脉畸形部分栓塞术后血管组织增殖与凋亡的变化[J]. 中华介入放射学电子杂志, 2022, 10(02): 152-157.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Effect of temozolomide on cell proliferation in TJ905 glioma stem cells with Livin over-expression

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Effect of temozolomide on cell proliferation in TJ905 glioma stem cells with Livin over-expression